uniQure N.V Market Cap ($1.42 Billion)
Market Cap & Net Worth: uniQure N.V (UQ1)
uniQure N.V market cap. uniQure N.V (F:UQ1) has a market capitalization of $1.42 Billion (€1.22 Billion) as of November 9, 2026. Listed on the F stock exchange, this Germany-based company holds position #7162 globally and #1022 in its home market, demonstrating a -14.22% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying uniQure N.V's stock price €19.30 by its total outstanding shares 63067485 (63.07 Million). Also see uniQure N.V (UQ1) cash flow conversion for how efficiently the company converts equity into cash flow.
uniQure N.V Market Cap History (2015–2026)
uniQure N.V market cap history from 2015 to 2026. Data shows growth from $1.03 Billion to $1.42 Billion (0.85% CAGR). Check uniQure N.V stock price for real-time trading data and today's change.
uniQure N.V Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how uniQure N.V's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore UQ1 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
94.54x
uniQure N.V's market cap is 94.54 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $393.07 Million | $25.10 Million | -$73.37 Million | 15.66x | N/A |
| 2017 | $1.18 Billion | $13.11 Million | -$79.26 Million | 89.92x | N/A |
| 2018 | $1.64 Billion | $11.28 Million | -$83.30 Million | 145.06x | N/A |
| 2019 | $4.70 Billion | $7.28 Million | -$124.20 Million | 646.08x | N/A |
| 2020 | $2.16 Billion | $37.51 Million | -$125.02 Million | 57.71x | N/A |
| 2021 | $1.32 Billion | $524.00 Million | $329.59 Million | 2.53x | 4.02x |
| 2022 | $1.54 Billion | $106.48 Million | -$126.79 Million | 14.50x | N/A |
| 2023 | $440.92 Million | $15.84 Million | -$308.48 Million | 27.83x | N/A |
| 2024 | $1.24 Billion | $27.12 Million | -$239.56 Million | 45.57x | N/A |
| 2025 | $1.52 Billion | $16.10 Million | -$198.97 Million | 94.54x | N/A |
Competitor Companies of UQ1 by Market Capitalization
Companies near uniQure N.V in the global market cap rankings as of November 9, 2026. Also see uniQure N.V total assets for a full breakdown of the balance sheet.
Key companies related to uniQure N.V by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of uniQure N.V (2015–2026)
Market capitalization of uniQure N.V from 2015 to today. Between 2015 and today, uniQure N.V's market cap moved from $1.03 Billion to $ 1.42 Billion, with a yearly change of 0.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.42 Billion | -6.49% |
| 2025 | €1.52 Billion | +23.15% |
| 2024 | €1.24 Billion | +180.27% |
| 2023 | €440.92 Million | -71.44% |
| 2022 | €1.54 Billion | +16.66% |
| 2021 | €1.32 Billion | -38.86% |
| 2020 | €2.16 Billion | -53.98% |
| 2019 | €4.70 Billion | +187.39% |
| 2018 | €1.64 Billion | +38.89% |
| 2017 | €1.18 Billion | +199.83% |
| 2016 | €393.07 Million | -61.88% |
| 2015 | €1.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 9th, 2026 the market cap of uniQure N.V was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.42 Billion USD |
| MoneyControl | $1.42 Billion USD |
| MarketWatch | $1.42 Billion USD |
| marketcap.company | $1.42 Billion USD |
| Reuters | $1.42 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more